NCT02525692 2024-12-24Oral ONC201 in Adult Recurrent GlioblastomaJazz PharmaceuticalsPhase 2 Terminated84 enrolled 14 charts 1 FDA
NCT04629209 2023-11-24A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaMasonic Cancer Center, University of MinnesotaPhase 2 Withdrawn